Zentalis Pharmaceuticals (ZNTL) Other Gross PP&E Adjustments (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Other Gross PP&E Adjustments came in at -$20.0 million in Q1 2026, up 23.95% year-on-year from -$16.2 million in Q1 2025, and up 27.24% quarter-over-quarter from -$27.5 million in Q4 2025.
Zentalis Pharmaceuticals has reported Other Gross PP&E Adjustments for 8 years, with the latest figure at -$20.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 23.95% year-over-year to -$20.0 million; the trailing twelve-month figure through Mar 2026 stood at -$20.0 million (up 23.95% YoY), and the FY2025 full-year result was -$27.5 million, up 8.41% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$20.0 million, up from -$27.5 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$20.0 million in Q1 2026, with the low at -$35.1 million in Q4 2022.
- Average Other Gross PP&E Adjustments over 5 years is -$28.2 million, with a median of -$27.2 million recorded in 2023.
- Year-over-year, Other Gross PP&E Adjustments tumbled 51495.45% in 2022 and advanced 23.95% in 2026.
- Tracing ZNTL's Other Gross PP&E Adjustments over 5 years: stood at -$35.1 million in 2022, then climbed by 5.01% to -$33.3 million in 2023, then increased by 9.88% to -$30.1 million in 2024, then rose by 8.41% to -$27.5 million in 2025, then advanced by 27.24% to -$20.0 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$20.0 million (Q1 2026), -$27.5 million (Q4 2025), and -$24.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -20.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.03 Mn |
| Mar 31, 2026 | -20.03 Mn |
| Dec 31, 2025 | -27.53 Mn |
| Dec 31, 2025 | -27.53 Mn |
| Sep 30, 2025 | -24.60 Mn |
| Sep 30, 2025 | -24.60 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -26.34 Mn |
| Mar 31, 2025 | -26.34 Mn |
| Dec 31, 2024 | -30.06 Mn |
| Dec 31, 2024 | -30.06 Mn |
| Sep 30, 2024 | -24.43 Mn |
| Sep 30, 2024 | -24.43 Mn |
| Jun 30, 2024 | -24.50 Mn |
| Jun 30, 2024 | -24.50 Mn |
| Mar 31, 2024 | -25.64 Mn |
| Mar 31, 2024 | -25.64 Mn |
| Dec 31, 2023 | -33.35 Mn |
| Dec 31, 2023 | -33.35 Mn |
| Sep 30, 2023 | -26.68 Mn |
| Sep 30, 2023 | -26.68 Mn |
| Jun 30, 2023 | -27.17 Mn |
| Jun 30, 2023 | -27.17 Mn |
| Mar 31, 2023 | -27.50 Mn |
| Mar 31, 2023 | -27.50 Mn |
| Dec 31, 2022 | -35.11 Mn |
| Dec 31, 2022 | -35.11 Mn |
| Sep 30, 2022 | -32.92 Mn |
| Sep 30, 2022 | -32.92 Mn |
| Jun 30, 2022 | -33.76 Mn |
| Jun 30, 2022 | -33.76 Mn |
| Mar 31, 2022 | -34.05 Mn |
| Mar 31, 2022 | -34.05 Mn |
| Dec 31, 2021 | -37.05 Mn |
| Dec 31, 2021 | -37.05 Mn |
| Sep 30, 2021 | 4.59 Mn |
| Sep 30, 2021 | 4.59 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Mar 31, 2021 | -66,000.00 |
| Mar 31, 2021 | -66,000.00 |
| Dec 31, 2020 | -1.17 Mn |
| Dec 31, 2020 | -1.17 Mn |
| Sep 30, 2020 | -1.23 Mn |
| Sep 30, 2020 | -1.23 Mn |
| Jun 30, 2020 | -1.42 Mn |
| Jun 30, 2020 | -1.42 Mn |
| Mar 31, 2020 | -1.55 Mn |
| Mar 31, 2020 | -1.55 Mn |
| Dec 31, 2019 | -1.67 Mn |
| Dec 31, 2019 | -1.67 Mn |